Reason for request
Reassessment
Clinical Benefit
| Insufficient |
The Committee deems that the clinical benefit of BLENREP (belantamab mafodotin) 100 mg, powder for solution for dilution for infusion, is insufficient in the MA indication to justify public funding.
|
Clinical Added Value
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
WGAeRLZ7nHu2zZGk